| Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.Prostate Cancer Prostatic Dis | PMID 38347114PMC11317541 | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double-dummy pilot trial.Headache | PMID 39290050PMC12129245 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39322611无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.J Sleep Res | PMID 39377364PMC12069729 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Treatment of early-onset fetal growth restriction with low molecular weight heparin does not prolong gestation: a randomized clinical trial.Am J Obstet Gynecol | PMID 39521297无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.Eur Urol Oncol | PMID 39521639PMC12059143 | 2025-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.Eur Urol | PMID 39537438无 PMCID | 2025-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE.Ophthalmol Retina | PMID 39580145无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial.Arthritis Rheumatol | PMID 39609094PMC12123255 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study.J Heart Lung Transplant | PMID 39613120无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.Chest | PMID 39622469无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial.J Card Fail | PMID 39653325无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer.Clin Colorectal Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39743478无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.Clin Obes | PMID 39800653PMC12096058 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial.Clin Colorectal Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39818468无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials.Eur J Heart Fail | PMID 39844714PMC12260334 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39884884无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis-A Safety Analysis.United European Gastroenterol J | PMID 39891572PMC12188354 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial.Addiction | PMID 39915904PMC12212235 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial.Clin Microbiol Infect | PMID 39922466PMC12068974 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials.Am Heart J | PMID 39952376无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.J Eur Acad Dermatol Venereol | PMID 39962358PMC12105426 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of elobixibat in patients with chronic constipation-A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India.Indian J Gastroenterol | PMID 39985701PMC12141165 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.Eye (Lond) | PMID 40000909PMC12089586 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder.J Psychopharmacol | PMID 40012166PMC12205165 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Harms of Morphine for Chronic Breathlessness in Relation to Dose, Duration and Titration Phase.J Pain Symptom Manage | PMID 40015533无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.J Urol | PMID 40080805PMC12064358 | 2025-Jun | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF.JACC Heart Fail | PMID 40088233无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40097073无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:森林图/亚组分析图;Fig. 5:森林图/亚组分析图;另有 2 张未列出。 | PMID 40097663PMC12176615 | 2025-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis.Cancer Sci | PMID 40099663PMC12127112 | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials.J Am Geriatr Soc | PMID 40105285PMC12205298 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.HIV Med | PMID 40116337PMC12127236 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinicopathological Factors Affecting Stomach Preservation Following Laparoscopic Sentinel Node Navigation Surgery in Patients with Early Gastric Cancer: A Secondary Analysis of the Multicenter Randomized Phase III SENORITA Trial.Ann Surg Oncol | PMID 40117015无 PMCID | 2025-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A Phase III Randomized, Double-Blind, Active-Controlled, Multicenter Study on the Efficacy and Safety of Ezetimibe/Atorvastatin/Amlodipine Combination in Patients With Comorbid Primary Hypercholesterolemia and Essential Hypertension.Clin Ther | PMID 40122716无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.Breast Cancer Res TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40140172无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses.J Allergy Clin Immunol | PMID 40154575无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG 4.:森林图/亚组分析图;FIG 5.:非 KM 图。 | PMID 40179324PMC12118624 | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Does the Burden of CSVD Modify the Efficacy of Dual Antiplatelet Therapy?: A Post Hoc Analysis of the INSPIRES Trial.Stroke | PMID 40190261无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial.Clin Genitourin Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40204616无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40217078无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis.Ann Clin Transl Neurol | PMID 40223516PMC12172114 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mepitel Film Versus StrataXRT in Managing Radiation Dermatitis in an Intra-Patient Controlled Clinical Trial of 80 Postmastectomy Patients.J Med Imaging Radiat Oncol | PMID 40223795PMC12175215 | 2025-Jun | 0.95 | The study is an oncology (breast cancer), human, randomized, Phase III trial reporting original results. However, it is ineligible because: 1) The primary endpoint is moist desquamation rate (a binary incidence outcome at a fixed time), not a time-to-event efficacy endpoint requiring Kaplan-Meier analysis or hazard ratios. 2) The interventions are Mepitel film and StrataXRT, which are medical devices/topical products, not drug-containing interventions. | 待处理 |
| Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease.Clin Res Hepatol Gastroenterol | PMID 40228712无 PMCID | 2025-Jun | 0.80 | The study is a randomized, double-blind, placebo-controlled Phase 3 trial of vedolizumab for Crohn's disease, which is not a malignant neoplasm. While it meets criteria for human, randomized, Phase 3, drug intervention, and original results, it is not an oncology study. Furthermore, the primary and secondary endpoints are clinical response and remission scores, not time-to-event outcomes. Therefore, it is ineligible. | 待处理 |
| Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.Mult Scler | PMID 40237070PMC12159353 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.Leukemia | PMID 40240572PMC12133573 | 2025-Jun | 0.95 | While the parent trial is an eligible oncology Phase III randomized drug trial, this specific report is a secondary analysis focused on patient-reported outcomes and quality of life, which are excluded per adjudication rules. The required primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) is not the subject of this report. | 待处理 |
| Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 40245915无 PMCID | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA).Drugs R D | PMID 40279006PMC12185822 | 2025-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40286809无 PMCID | 2025-Jun | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40300278无 PMCID | 2025-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |